
The GLP-1 weight loss drug market presents a massive opportunity, with Eli Lilly (LLY) positioned for significant long-term growth as it aims for over $100 billion in sales by 2034. For foundational AI exposure, NVIDIA (NVDA) remains the dominant leader with a potential path to $500 billion in revenue by 2026, though investors should be mindful of its high valuation. As a compelling alternative, Advanced Micro Devices (AMD) is rapidly gaining market share in AI chips and offers a way to invest in the same trend with potentially more upside. Beyond hardware, consider Google (GOOGL) and Microsoft (MSFT) as they leverage vast resources and strategic partnerships to dominate the AI software and cloud ecosystem. Conversely, be cautious with Apple's (AAPL) current AI strategy, which is viewed as lagging competitors, and avoid companies heavily reliant on the increasingly stressed private credit market.

By John Coogan & Jordi Hays
Technology's daily show (formerly the Technology Brothers Podcast). Streaming live on X and YouTube from 11 - 2 PM PST Monday - Friday. Available on X, Apple, Spotify, and YouTube.